Page last updated: 2024-12-06

raxofelast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Raxofelast: prodrug of IRFI-005 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65961
CHEMBL ID2105376
SCHEMBL ID633619
MeSH IDM0193174

Synonyms (22)

Synonym
raxofelast
irfi-016
2-benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-, (+-)-
2-benzofuranacetic acid, 2,3-dihydro-5-(acetyloxy)-4,6,7-trimethyl-, (+-)-
(+-)-2,3-dihydro-5-(acetyloxy)-4,6,7-trimethyl-2-benzofuranacetic acid
irfi 016
raxofelast [inn]
(+-)-2,3-dihydro-5-hydroxy-4,6,7-trimethyl-2-benzofuranacetic acid, acetate
2-(5-acetyloxy-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-2-yl)acetic acid
unii-tc0t0o9vyo
tc0t0o9vyo ,
128232-14-4
CHEMBL2105376
SCHEMBL633619
(rs)-2-(2,3-dihydro-5-acetyloxy-4,6,7-trimethylbenzofuranyl) acetic acid
QLWBKUUORSULMI-UHFFFAOYSA-N
2-(5-acetoxy-4,6,7-trimethyl-2,3-dihydrobenzofuran-2-yl)acetic acid
DTXSID80926097
[5-(acetyloxy)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-2-yl]acetic acid
FT-0749081
Q27289886
AKOS040753711

Research Excerpts

Overview

Raxofelast is a potent antioxidant agent under investigation, structurally related to VE. It has an excellent bioavailability and favourable physicochemical properties.

ExcerptReferenceRelevance
"Raxofelast is a potent antioxidant agent under investigation, structurally related to VE, having an excellent bioavailability and favourable physicochemical properties."( Beneficial effect of raxofelast, an hydrophilic vitamin E analogue, in the rat heart after ischemia and reperfusion injury.
Altavilla, D; Avenoso, A; Campo, GM; Campo, S; Caputi, AP; Ceccarelli, S; Ferlito, M; Quartarone, C; Saitta, A; Squadrito, F; Squadrito, G, 1998
)
1.34

Treatment

ExcerptReferenceRelevance
"Oral treatment with raxofelast for 1 week reduces oxidative stress and improves endothelial function in men with Type II diabetes."( Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes.
AnggÄrd, EE; Brett, SE; Chowienczyk, PJ; Gopaul, NK; Marchetti, M; Meeking, D; Ritter, JM; Russell-Jones, DL, 2000
)
0.91

Bioavailability

ExcerptReferenceRelevance
" Raxofelast is a potent antioxidant agent under investigation, structurally related to VE, having an excellent bioavailability and favourable physicochemical properties."( Beneficial effect of raxofelast, an hydrophilic vitamin E analogue, in the rat heart after ischemia and reperfusion injury.
Altavilla, D; Avenoso, A; Campo, GM; Campo, S; Caputi, AP; Ceccarelli, S; Ferlito, M; Quartarone, C; Saitta, A; Squadrito, F; Squadrito, G, 1998
)
1.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (40.00)18.2507
2000's12 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]